{"prompt": "['Novartis', 'Confidential', 'Page 50', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '3. Deterioration in lung function, which last for two days or more but usually not severe', 'enough to warrant SCSs for more than 2 days or hospitalization. This deterioration would', 'be defined by:', '> 20% decrease in FEV1 from baseline value', 'Or', '> 20% decrease in morning (AM) or evening (PM) PEF from baseline on 2 out of any', '3 consecutive days compared to baseline.', 'Or', '< 60% of predicted PEF compared to baseline', 'A mild asthma exacerbation is defined as the occurrence of one of the following criteria:', '1. Deterioration of at least one asthma symptoms like shortness of breath, cough, wheezing', 'or chest tightness.', '2. Increased use of \"rescue\" inhaled bronchodilators', '3. Deterioration in lung function, which last for two days or more but usually not severe', 'enough to warrant SCSs or hospitalization. This deterioration would be defined by:', '> 20% decrease in FEV1 from baseline value', 'Or', '> 20% decrease in morning (AM) or evening (PM) PEF from baseline on 2 out of any', '3 consecutive days compared to baseline.', 'Or', '< 60% of predicted PEF compared to baseline', '\"Start and end dates\" of each reported event in the CRF will be used to determine whether', 'two consecutively reported events should be considered as separate events or as a prolonged', 'one. If a second exacerbation is reported less than 7 days after the end date of a previous', 'episode, then this will be assumed to be one continuous exacerbation with the start date taken', 'from the first episode and the end date from the second or last episode. If two events are', 'merged based on this \"7 day rule\", the highest reported severity will be used to describe the', 'overall severity of the prolonged event.', 'The treatment of asthma exacerbations including the initiation of SCS or increase in the', \"maintenance dose of OCS should be done according to investigator's or treating physician's\", 'medical judgement and should be in line with national and international recommendations. If', 'SCS are required, a patient may return to the study after successfully completing a taper.']['Novartis', 'Confidential', 'Page 51', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6.4.7 Appropriateness of efficacy assessments', 'The efficacy assessments selected are standard for this indication/patient population.', 'The primary endpoint, Asthma Quality of Life (AQLQ), refers to the perceived impact that', \"asthma has on the patient's quality of life (QoL). This endpoint is widely used in asthma trials\", 'and in more than six published validation studies conducted worldwide and has shown very', 'strong measurement properties. It is increasingly recognized that the evaluation of therapeutic', 'interventions should include assessment of outcomes that matter to patients. The QOL', 'measures can provide unique information and can thus provide a more complete', \"characterization of the study population's asthma and of the benefits or drawbacks of\", 'particular interventions.', '6.5 Safety', 'The following safety assessments will be performed:', 'Medical history and physical examination', 'Vital signs', 'Hematology, Blood chemistry, Urinalysis', 'ECG', 'Adverse events including serious adverse events', 'Pregnancy (female patients); additional pregnancy testing might be performed if requested', 'by local requirements', 'Serious asthma outcomes (asthma-related hospitalizations, intubations or deaths)', 'CCV events and new onset of atrial fibrillation', 'An independent adjudication committee will be established to assess serious asthma outcomes', '(asthma-related hospitalizations, intubations and deaths), serious cardiovascular and', 'cerebrovascular (CCV) events, new onset of atrial fibrillation and flutter as well as all deaths.', 'Refer to Section 8.5 for more information.', '6.5.1 Physical examination', 'A complete physical examination will include the examination of general appearance, skin,', 'neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes,', 'extremities, vascular and neurological. If indicated based on medical history and/or', 'symptoms, rectal, external genitalia, breast, and pelvic exams will be performed as detailed in', 'Schedule of Assessments Table 6-1.', 'Information for all physical examinations must be included in the source documentation at the', 'study site. Significant findings that are present prior to informed consent being signed must be', \"included in the Relevant Medical History/Current Medical Conditions screen on the patient's\", 'eCRF. Significant findings made after informed consent (Visit 1) is given which meet the', 'definition of an Adverse Event must be recorded on the Adverse Event eCRF.']\n\n###\n\n", "completion": "END"}